4.5 Article

Low RAI2 expression is a marker of poor prognosis in breast cancer

Journal

BREAST CANCER RESEARCH AND TREATMENT
Volume 187, Issue 1, Pages 81-93

Publisher

SPRINGER
DOI: 10.1007/s10549-021-06176-w

Keywords

Breast cancer; Retinoic acid-induced 2 (RAI2); Disseminated tumor cells (DTC)

Categories

Funding

  1. Ministry of Education, Culture, Sports, Science, and Technology of Japan (MEXT) KAKENHI [16K10468]
  2. Grants-in-Aid for Scientific Research [16K10468] Funding Source: KAKEN

Ask authors/readers for more resources

The study found significant associations between low RAI2 mRNA expression and shorter disease-free survival, breast cancer-specific survival, and overall survival in breast cancer patients. Negative RAI2 protein expression was also related to shorter survival periods. Both low RAI2 mRNA and negative RAI2 protein expression were correlated with larger tumor size, higher tumor grade, and ER alpha-negativity. Multivariate analyses showed that both RAI2 mRNA and protein expression were independent risk factors for disease-free survival and breast cancer-specific survival.
Purpose Retinoic acid-induced 2 (RAI2) has been shown to be a putative suppressor of the early hematogenous dissemination of tumor cells to the bone marrow in breast cancer. Here, we investigated the associations of RAI2 mRNA and protein expression with clinicopathological factors and prognosis in breast cancer patients with long-term follow-up. Methods Invasive breast cancer tissues (n = 604) were analyzed for RAI2 mRNA expression. We examined the associations of clinicopathological factors with the expression levels of RAI2 mRNA in these samples. We also analyzed RAI2 protein expression by immunohistochemistry in invasive breast cancer tissues (n = 422). Results We identified significant positive associations between low expression of RAI2 mRNA and shorter disease-free survival (DFS), breast-cancer-specific survival (BCSS), and overall survival (OS) in breast cancer patients. We also identified significant positive associations between negative for RAI2 protein expression and shorter DFS, BCSS, and OS in breast cancer patients. Low RAI2 mRNA and negative for RAI2 protein expression were positively associated with larger tumor size, higher tumor grade, and ER alpha-negativity. Multivariate analyses indicated that not only RAI2 mRNA but also RAI2 protein expression were independent risk factors for both DFS and BCSS in breast cancer patients. The median follow-up periods were 10.3 and 9.3 years for the RAI2 mRNA and protein expression analyses, respectively. Conclusions Our findings suggest that RAI2 has a role in the metastasis of breast cancer, and that RAI2 expression could be a promising candidate biomarker of prognosis in breast cancer patients.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available